Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics ...

ON THIS PAGEWhy Urgency Happens in UCSolutions for UC UrgencyWhen Urgency Is a Bigger ProblemMore than80 percent of people with ulcerative colitis (UC) experience bowel urgency that overwhelming, need ...

These easy weeknight-friendly dinner recipes are high in protein, heart-healthy, and avoid common trigger foods to help ...

For most people, talking about poop is uncomfortable, but if you live with ulcerative colitis (UC), a form of inflammatory bowel disease (IBD), it’s unavoidable — and it’s a crucial part of disease ...

At week 140, 80.8% of those administered guselkumab achieved clinical remission.

New ECCO dietary therapy guidelines for IBD clarify the role of enteral nutrition, Mediterranean diet, supplements, and RD ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...

Indiana University School of Medicine scientists have uncovered new evidence that an age-related blood condition may contribute to inflammatory bowel disease (IBD). Their findings suggest that a new ...

STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained ...